BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $34 to $36.